Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma

"Novel Bispecific Checkpoint Inhibition:~QL1706(iparomlimab and Tuvonralimab) was generated by using MabPair, a new technological platform that enables the production of two antibodies close to their natural forms from a single host cell line and is manufactured as one product. QL1706 contains a mixture of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 that were produced together in a fixed ratio. Each antibody was individually optimized to achieve desirable target coverage and antibody effector functions.~Chemotherapy for first-line treatment (pemetrexed plus cisplatin or carboplatin )~Chemotherapy for second-line treatment (pemetrexed, gemcitabine or vinorelbine)"